Pancreatic Cancer Research

ResearcherErasmus MCActive in the last 2 years

Mustafa Suker

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7935-4666; OpenAlex author ID A5003973735. Sources: OpenAlex.

Their work

Papers
20 (first author 3, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
96
Papers, trials and grants by year

2016: 2 papers · 2017: 1 paper · 2018: 1 paper · 2019: 6 papers · 2020: 2 papers · 2021: 1 paper · 2022: 4 papers · 2023: 2 papers · 2024: none · 2025: 1 paper

Papers 20

  1. Delayed gastric emptying after pancreatic cancer surgery impacts time to start of adjuvant treatment but not overall survival: a post-hoc analysis of the PREOP… Co-author DOI 10.1093/bjs/znaf261↗
  2. The yield of staging laparoscopy for resectable and borderline resectable pancreatic cancer in the PREOPANC randomized controlled trial. Last author DOI 10.1016/j.ejso.2022.12.011↗
  3. Predictive value of baseline serum carbohydrate antigen 19-9 level on treatment effect of neoadjuvant chemoradiotherapy in patients with resectable and borderl… Co-author DOI 10.1093/bjs/znad210↗
  4. Surgical Complications in a Multicenter Randomized Trial Comparing Preoperative Chemoradiotherapy and Immediate Surgery in Patients With Resectable and Borderl… First author DOI 10.1097/sla.0000000000004313↗
  5. External Validity of the Multicenter Randomized PREOPANC Trial on Neoadjuvant Chemoradiotherapy in Pancreatic Cancer: Outcome of Eligible but Nonrandomized Pat… First author DOI 10.1097/sla.0000000000004364↗
  6. Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREO… Co-author DOI 10.1200/jco.21.02233↗
  7. High Systemic Immune Inflammation Index Is Associated With Low Skeletal Muscle Quantity in Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fonc.2022.827755↗
  8. A phase II study of stereotactic radiotherapy after FOLFIRINOX for locally advanced pancreatic cancer (LAPC-1 trial): Long-term outcome. Co-author DOI 10.1016/j.radonc.2020.11.006↗
  9. The yield of chest computed tomography in patients with locally advanced pancreatic cancer. Co-author DOI 10.1002/jso.25968↗
  10. Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III P… First author DOI 10.1200/jco.19.02274↗
  11. Efficacy and feasibility of stereotactic radiotherapy after folfirinox in patients with locally advanced pancreatic cancer (LAPC-1 trial). Co-author DOI 10.1016/j.eclinm.2019.10.013↗
  12. Yield of staging laparoscopy before treatment of locally advanced pancreatic cancer to detect occult metastases. Co-author DOI 10.1016/j.ejso.2019.06.004↗
  13. Pancreatic cancer treated with SBRT: Effect of anatomical interfraction variations on dose to organs at risk. Co-author DOI 10.1016/j.radonc.2019.01.020↗
  14. Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. Co-author DOI 10.1093/jnci/djz073↗
  15. The Systemic-immune-inflammation Index Independently Predicts Survival and Recurrence in Resectable Pancreatic Cancer and its Prognostic Value Depends on Bilir… Co-author DOI 10.1097/sla.0000000000002660↗
  16. Immune-Related Circulating miR-125b-5p and miR-99a-5p Reveal a High Recurrence Risk Group of Pancreatic Cancer Patients after Tumor Resection. Co-author DOI 10.3390/app9224784↗
  17. FOLFIRINOX and radiotherapy for locally advanced pancreatic cancer: A cohort study. Co-author DOI 10.1002/jso.25233↗
  18. Quality assurance of the PREOPANC trial (2012-003181-40) for preoperative radiochemotherapy in pancreatic cancer : The dummy run. Co-author DOI 10.1007/s00066-017-1153-6↗
  19. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Co-author DOI 10.1016/s1470-2045(16)00172-8↗
  20. Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multi… Co-author DOI 10.1186/s13063-016-1262-z↗

Closest collaborators

The 25 strongest of 96 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Casper H.J. van Eijck · 19 shared papers, 2016–2023 · strength 1.90
  2. Bas Groot Koerkamp · 13 shared papers, 2016–2023 · strength 1.29
  3. Bert A. Bonsing · 10 shared papers, 2016–2023 · strength 1.01
  4. Joost J.M.E. Nuyttens · 8 shared papers, 2018–2023 · strength 0.89
  5. Geertjan van Tienhoven · 9 shared papers, 2016–2023 · strength 0.88
  6. Eva Versteijne · 8 shared papers, 2016–2023 · strength 0.82
  7. Marc G. Besselink · 8 shared papers, 2016–2023 · strength 0.81
  8. Ignace H. J. T. de Hingh · 7 shared papers, 2016–2023 · strength 0.75
  9. Ferry A.L.M. Eskens · 6 shared papers, 2018–2022 · strength 0.65
  10. J. Sven D. Mieog · 6 shared papers, 2019–2023 · strength 0.65
  11. Gijs A. Patijn · 6 shared papers, 2016–2023 · strength 0.62
  12. Sebastiaan Festen · 6 shared papers, 2016–2023 · strength 0.62
  13. Marjolein Y.V. Homs · 5 shared papers, 2019–2023 · strength 0.49
  14. Judith de Vos‐Geelen · 5 shared papers, 2016–2023 · strength 0.48
  15. Jelle C. van Dongen · 3 shared papers, 2022–2023 · strength 0.40
  16. Johanna W. Wilmink · 4 shared papers, 2019–2023 · strength 0.36
  17. Izaak Quintus Molenaar · 3 shared papers, 2016–2023 · strength 0.30
  18. Vincent Erwin de Meijer · 2 shared papers, 2023 · strength 0.27
  19. Mauro Loi · 2 shared papers, 2019–2021 · strength 0.26
  20. Jesse V. Groen · 2 shared papers, 2022 · strength 0.26
  21. Jacob L. van Dam · 2 shared papers, 2022–2023 · strength 0.23
  22. Mohammad Hosein Aziz · 2 shared papers, 2019–2022 · strength 0.21
  23. Kostandinos Sideras · 2 shared papers, 2019–2022 · strength 0.21
  24. Marion B.M. van der Kolk · 2 shared papers, 2016–2023 · strength 0.18
  25. Jeanin Elise van Hooft · 2 shared papers, 2020–2022 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.